Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC) Meeting Abstract


Authors: Dickler, M.; Rugo, H.; Caravelli, J.; Brogi, E.; Sachs, D.; Panageas, K.; Flores, S.; Moasser, M.; Norton, L.; Hudis, C.
Abstract Title: Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC)
Meeting Title: 40th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 22
Issue: 14 Suppl.
Meeting Dates: 2004 Jun 5-8
Meeting Location: New Orleans, LA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2004-07-15
Start Page: 127S
Language: English
ACCESSION: WOS:000223512400503
PROVIDER: wos
Notes: Meeting Abstract: 2001 -- 40th Annual Meeting of the American-Society-of-Clinical-Oncology -- JUN 05-08, 2004 -- New Orleans, LA -- S -- Source: Wos
MSK Authors
  1. Mark M Moasser
    56 Moasser
  2. Clifford Hudis
    848 Hudis
  3. Larry Norton
    580 Norton
  4. Maura N Dickler
    238 Dickler
  5. Dana L Sachs
    23 Sachs
  6. Katherine S Panageas
    331 Panageas
  7. Edi Brogi
    306 Brogi
  8. Sally A Flores
    3 Flores
Related MSK Work